Mr. Rodger Seccombe reports

AVRICORE HEALTH CLOSES $1.254 MILLION FINANCING

Further to Avricore Health Inc.'s news release dated May 20, 2026, the company has closed its non-brokered private placement for gross proceeds of $1,254,000 by issuing 25.08 million units at five cents per unit on June 16, 2026.

Rodger Seccombe, chief executive officer of Avricore, stated: "This financing provides the company with the capital strength for its U.K. expansion. We appreciate the commitment from our investors as we prepare to execute on our growth strategy."

Each unit consists of one common share and one-half transferrable share purchase warrant. Each warrant will entitle the holder thereof to purchase one additional common share for a period of two years from the closing date of the offering at a price of 10 cents per common share. The company will pay finders' fees totalling $54,600 and issue 1,092,000 non-transferable finders' warrants to Canaccord Genuity Corp. an arm's-length finder. The finders' warrants are exercisable at five cents for two years from the closing date.

Closing of the private placement is subject to final acceptance by the TSX Venture Exchange. All securities issued in connection with the private placement will be subject to a four-month hold period from the closing date under applicable Canadian securities laws. Placement proceeds will be used for general working capital purposes.

Insiders participated in the aggregate amount of $200,000 for four million units. Certain directors and officers have participated in the private placement. Such participation is considered a related party transaction within the meaning of Multilateral Instrument 61-101 -- Protection of Minority Security Holders in Special Transactions. The related party transaction will be exempt from minority approval, information circular and formal valuation requirements pursuant to the exemptions contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the gross securities to be issued under the private placement nor the consideration to be paid by the insiders will exceed 25 per cent of the company's market capitalization. A material change report will be filed less than 21 days before the closing date of the transactions contemplated by this news release. The company believes this shorter period is reasonable and necessary in the circumstances.

HealthTab at the core of scalable, integrated POCT

HealthTab is a complete, turnkey solution for community-based POCT networks, combining best-in-class instruments, cloud software, standardized workflows, and comprehensive training and support. At its centre is a secure, cloud-based platform that seamlessly connects point-of-care analyzers, patient results and QC data into a unified digital infrastructure for distributed testing environments. This fully integrated approach ensures quality-assured testing, consistent data capture across all locations, and real-time analytics for public-health reporting and performance monitoring, while significantly reducing implementation complexity for participating sites.

Commitment to quality and accuracy

HealthTab is designed to meet the highest standards of analytical performance and reliability. Through its partnership with CEQAL Inc., a world-leading reference method laboratory and member of the CDC Cholesterol Reference Method Laboratory Network (CRMLN), HealthTab operates a comprehensive quality management program that mirrors the rigour of accredited clinical laboratories.

The program includes centralized lot monitoring of reagents, internal quality-control procedures, regular external quality-assessment (EQA) events, and expert oversight services to support the accuracy, consistency and traceability of results to internationally recognized reference standards across participating sites.

About Avricore Health Inc.

Avricore Health is a pharmacy service innovator focused on acquiring and developing early stage technologies aimed at advancing pharmacy practice and patient care. Through its flagship offering HealthTab, a wholly owned subsidiary, the company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

We seek Safe Harbor.